Physician profile
Michelle E Marosok
NPI 1669166112
$6,546.27
in general payments reported to CMS, 2019-2025
44 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,551 · 2024: $3,331 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,168 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,167.54 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,710.37 | 2023-2025 | |
| Janssen Biotech, INC. | $639.35 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Abbvie INC. | $429.06 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $366.10 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $330.96 | 2023-2025 | Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $300.16 | 2023-2024 | Ninlaro, Fruzaqla, Iclusig |
| Pfizer INC. | $280.93 | 2023-2025 | |
| Eisai INC. | $243.03 | 2023-2025 | |
| Sobi, INC | $197.14 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.04 | 2023-2025 | |
| Daiichi Sankyo INC. | $173.74 | 2023-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $166.22 | 2023-2025 | |
| Emd Serono, INC. | $156.55 | 2023-2024 | Bavencio |
| Exelixis INC. | $141.16 | 2023-2025 | Cabometyx |
| Beigene USA, INC. | $131.02 | 2023-2024 | Brukinsa |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $91.51 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Seagen INC. | $85.11 | 2023 | Tivdak, Padcev |
| Array Biopharma INC | $79.61 | 2023-2024 | Mektovi, Lorbrena, Xalkori |
| Mirati Therapeutics, INC. | $73.19 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $72.86 | 2023-2024 | Ojjaara |
| Pharmaessentia USA Corporation | $64.39 | 2024 | Besremi |
| Regeneron Healthcare Solutions, INC. | $63.48 | 2023-2024 | Libtayo |
| Celgene Corporation | $61.37 | 2023-2024 | Reblozyl, Pomalyst |
| Incyte Corporation | $57.33 | 2023-2024 | Jakafi |
| Astellas Pharma US INC | $52.70 | 2023 | Xospata |
| Accord Healthcare, INC. | $37.80 | 2023-2024 | |
| Fresenius Kabi USA, LLC | $29.47 | 2023 | Stimufend |
| Pharmacyclics LLC, An Abbvie Company | $29.16 | 2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $25.47 | 2024 | Ultomiris |
| Genmab U.S., INC. | $23.96 | 2024 | Epkinly |
| Blueprint Medicines Corporation | $23.70 | 2023 | Ayvakit |
| Stemline Therapeutics INC. | $21.83 | 2023 | Orserdu |
| Morphosys, US INC. | $21.77 | 2023 | Monjuvi |
| Deciphera Pharmaceuticals INC. | $21.27 | 2024 | Qinlock |
| Jazz Pharmaceuticals INC. | $19.96 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.86 | 2025 | Opdivo |
| Coherus Oncology, INC. | $17.59 | 2024 | |
| Puma Biotechnology, INC. | $17.28 | 2023 | Nerlynx |
| Pharmacosmos Therapeutics INC. | $15.79 | 2024 | Cosela |
| Kyowa Kirin, INC. | $15.47 | 2023 | Poteligeo |
| Karyopharm Therapeutics INC. | $15.33 | 2023 | Xpovio |
| Sun Pharmaceutical Industries INC. | $15.21 | 2024 | |
| Menarini Silicon Biosystems, INC. | $14.29 | 2023 | Cellsearch |
| Lilly USA, LLC | $13.68 | 2025 | Verzenio, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Marosok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.